ADMA BIOLOGICS Reports 77.3% Increase in Total Revenue for Q2 FY2023
August 22, 2023
☀️Earnings Overview
For the second quarter of FY2023, ADMA BIOLOGICS ($NASDAQ:ADMA) recorded total revenue of USD 60.1 million – a 77.3% increase compared with the same period last year. Net income came in at USD -6.4 million, representing a significant improvement from the -13.8 million reported in Q2 FY2022.
Analysis
GoodWhale has conducted an analysis of ADMA BIOLOGICS‘ fundamentals. According to Star Chart, ADMA BIOLOGICS is strong in terms of assets and growth, but weak when it comes to dividends and profitability. Furthermore, the health score of this company is low, at 3/10, indicating that ADMA BIOLOGICS is less likely to survive any crisis without the risk of bankruptcy. ADMA BIOLOGICS has been classified as a ‘cheetah’ type of company. This type of company is characterized by high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who may be interested in such a company would be those who are willing to take on more risk in exchange for higher returns. These investors may also be attracted to the potential for high growth and returns, despite the associated risks. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Adma Biologics. More…
| Total Revenues | Net Income | Net Margin |
| 208.11 | -40.29 | -19.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adma Biologics. More…
| Operations | Investing | Financing |
| -41.45 | -9.95 | 61.49 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adma Biologics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 343.03 | 196.26 | 0.65 |
Key Ratios Snapshot
Some of the financial key ratios for Adma Biologics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 77.4% | – | -8.0% |
| FCF Margin | ROE | ROA |
| -24.7% | -7.1% | -3.0% |
Peers
The company’s competitors include Avid Bioservices Inc, Alpha Tau Medical Ltd, and MediWound Ltd.
– Avid Bioservices Inc ($NASDAQ:CDMO)
Avid Bioservices Inc is a biopharmaceutical company that focuses on the development and commercialization of products to treat life-threatening diseases. The company has a market cap of 1.05B as of 2022 and a return on equity of 3.93%. Avid Bioservices Inc’s products are designed to treat patients with cancer, infectious diseases, and other life-threatening conditions.
– Alpha Tau Medical Ltd ($NASDAQ:DRTS)
Tau Medical Ltd is a biotechnology company that focuses on the development of targeted cancer therapies. The company has a market capitalization of 289.85 million as of 2022 and a return on equity of -7.6%. The company’s products are designed to improve the treatment of cancer by targeting specific cells and proteins that are associated with the disease. Tau Medical’s products are currently in clinical trials and have shown promise in the treatment of various types of cancer.
– MediWound Ltd ($NASDAQ:MDWD)
MediWound Ltd is a company that focuses on providing treatments for wounds. The company has a market cap of 54.18M as of 2022 and a return on equity of 201.37%. The company has been able to maintain a strong market share due to its focus on innovation and providing effective treatments for wounds.
Summary
ADMA Biologics has reported strong growth in total revenue for the second quarter of its FY2023, with a 77.3% year-on-year increase. Although the company reported a net income loss of -6.4 million, it is a significant improvement from the -13.8 million reported in the same quarter of the previous year. For investors, this indicates that the company’s strategy to restore profitability is on track and presents an attractive investment opportunity. With strong revenue growth and a recovering net income position, ADMA Biologics is a stock worth considering for investors looking for long-term returns.
Related Posts
Recent Posts
